## **International Agency for Research on Cancer**



Governing Council Fifty-eighth Session

GC/58/19 15/03/2016

Lyon, 19–20 May 2016 Auditorium

## GUIDANCE ON NOMINATIONS FOR THE REPLACEMENT OF SCIENTIFIC COUNCIL MEMBERS

- 1. In recent years, the Governing Council considered it had on occasion received insufficient information on which to base its choice of Scientific Council candidates. Participating States nominate candidates with excellent qualifications, but appointments need to ensure the maintenance of a balance of expertise within the Scientific Council. In addition, nominations from Participating States are frequently received after the deadline for document submission by the Secretariat, providing inadequate time for Participating States to evaluate the nominations in advance of the Governing Council session.
- 2. In January 2016, the Scientific Council discussed various options to achieve a better balance among its members, taking into account the Scientific Council's needs in terms of areas of expertise and other criteria such as gender balance, and recommended closer interaction between the outgoing Scientific Council members and their respective Governing Council Representatives in identifying candidates (see <a href="Document GC/58/4">Document GC/58/4</a>). The Scientific Council also recommended that two candidates should be submitted by the Participating States in order to provide more flexibility to the Governing Council in achieving the required range of expertise within the Scientific Council. Finally, the Scientific Council recognized that submission of candidates should be made as early as possible in the process to allow Governing Council members to review qualifications before voting.
- 3. The Governing Council has the opportunity to use their 58<sup>th</sup> session to try applying the recommendations received from the Scientific Council in the selection of new members. Accordingly, the Director contacted outgoing Scientific Council members shortly after the 52<sup>nd</sup> session to provide an assessment of the expertise required among incoming candidates to facilitate discussions with the Governing Council members.
- 4. Five Scientific Council members reached the end of their mandate at the last session (outgoing members highlighted in yellow in the table below). The Director analysed the areas of expertise among the remaining Scientific Council members and asked for nominations in 2016 in the fields of: cancer biology; molecular pathology; prevention and implementation research; health services and policy; cancer biostatistics and molecular epidemiology.
- 5. For the information of the Governing Council, the current expertise on the Scientific Council is presented in the table below.

Name	Country	Term of office	Gender	Field of expertise
Dr Boris Ya. Alekseev	Russian Federation	2016 – 2019	M	Clinical oncology; cancer biomarkers; urology
Dr Al-Hareth Al-Khater	Qatar	2014 – 2017	M	Haematology and oncology; implementation of cancer prevention and screening programmes
<mark>Dr Nuria</mark> Aragonés	<mark>Spain</mark>	2013 – 2016	F	Descriptive epidemiology; cancer epidemiology; environmental public health
Professor Jonas Bergh	Sweden	2016 – 2019	M	Clinical oncology; cancer biomarkers; breast cancer
Professor James F. Bishop	Australia	2013 – 2016	M	Cancer chemotherapy; clinical trials; cancer epidemiology; cancer health services and economics; health policy
Professor Jenny Chang-Claude	Germany	2016 – 2019	F	Genetic epidemiology; breast, ovarian and colorectal cancers
Professor Stephen J. Chanock	USA	2015 – 2018	M	Genetics; cancer epidemiology
Professor Françoise Clavel- Chapelon	France	2014 – 2017	F	Hormonal, reproductive factors and diet in disease outcomes
Dr Jerome Coffey	Ireland	2016 – 2019	M	The management of breast and urological cancers, especially testicular germ cell tumours and prostate
Dr Eugenia Dogliotti	Italy	2016 – 2019	F	Mechanisms of DNA repair and mutagenesis; molecular cancer epidemiology
Professor Karima El Rhazi	Morocco	2016 – 2019	F	Cancer epidemiology and public health; cancer control; tobacco and respiratory epidemiology; nutritional epidemiology; quality of life
Professor Kadir Mutlu Hayran	Turkey	2016 – 2019	M	Cancer epidemiology; cancer prevention; cancer clinical trials
Professor Lukas A. Huber	Austria	2014 – 2017	M	Molecular cell biology, cell signalling and translational cancer research
Professor Nicholas C. Jones	<mark>UK</mark>	2013 – 2016	M	Transcriptional regulation by signal transduction pathways; cancer biology
Professor Ellen Kampman	The Netherlands	2015 – 2018	F	Human nutrition; multifactorial causes of cancer, including diet and genetic susceptibility

Name	Country	Term of office	Gender	Field of expertise
Professor Lalit Kumar	India	2016 – 2019	M	Clinical oncology; bone marrow/stem cell transplantation; multiple myeloma; gynecological malignancies
Dr Dukhyoung Lee	Republic of Korea	2016 – 2019	M	Cancer prevention and control; cancer surveillance
Dr Luis Felipe Ribeiro Pinto	Brazil	2014 – 2017	M	Mechanisms of carcinogenesis; molecular epidemiology; epigenetics and somatic mutations in relation to etiological factors; developing biomarkers of early detection or targeted therapies in upper aerodigestive tract tumours
Dr Ole Raaschou- Nielsen	Denmark	2015 – 2018	M	Epidemiology; cancer, environment; exposure assessment; air pollution and health, especially cancer using a molecular epidemiological approach
Professor Martin Röösli	Switzerland	2015 – 2018	M	Environmental epidemiology, including exposure assessment, etiological research and health risk assessments
Professor Christos Sotiriou	Belgium	2013 – 2016	M	Translational cancer research; breast cancer; clinical cancer biomarkers
Dr John Spinelli	Canada	2014 – 2017	M	Biostatistical and epidemiological methods; genetic and environmental risks for cancer, including lymphoproliferative cancers
Professor Giske Ursin	Norway	2016 – 2019	F	Cancer registration; cancer epidemiology; nutritional epidemiology; geneenvironment interactions
Professor Elisabete Weiderpass- Vainio	Finland	2015 – 2018	F	Cancer epidemiology
Dr Teruhiko Yoshida	Japan	2013 – 2016	M	Cancer genetics and genomics; clinical medical genetics of hereditary cancer syndromes; cancer gene therapy
			TOTAL <b>F = 8</b> M = 17	